Evotec SE
NASDAQ:EVODrug Manufacturers - Specialty & Generic
-$0.02 today
- Market cap
- $518.56M
- Beta
- 1.30
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$1.09
Volume 0.04M
Average 0.08M
EVO Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Evotec SENASDAQ: EVO
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue declines year over year
Q1 FY2026 cost of revenue of €160.81M fell 6.9% year over year, behind the -3.0% change in trailing-twelve-month cost of revenue. Sequentially, it fell 7.1% from the prior quarter. Over 3 fiscal years it compounded at +6.4% a year.
Context
- Cost of revenue amounted to 91.7% of revenue in FY2025, up 6.1 pp from a year earlier.
- Cost of revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -6.9% toward the trailing-twelve-month pace of -3.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
EUR · from the income statement
- Latest · FY2025
- 694.6M EUR
- Year-over-year change
- +1.8%
- 4-year CAGR
- +10.5%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 694.6M | +1.8% |
| FY2024 | 2024-12-31 | 682.09M | +12.5% |
| FY2023 | 2023-12-31 | 606.38M | +5.0% |
| FY2022 | 2022-12-31 | 577.38M | +23.8% |
| FY2021 | 2021-12-31 | 466.49M | — |
Cost of Revenue vs competitors
How EVO compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -3.0% is the 9th highest of 11, against a peer median of +8.2%.
- Cost of revenue amounts to 88.6% of revenue for EVO, versus a peer median of 38.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $864.58M USD | +14.7% | +1.2% | 34.4% | |
| LTM Feb 2026 | $854.85M USD | +7.8% | +7.3% | 72.3% | |
| LTM Mar 2026 | €660.57M EUR | -3.0% | +6.4% | 88.6% | |
| LTM Sep 2026 | $346.74M USD | +8.6% | -7.1% | 55.8% | |
| LTM Mar 2026 | $216.2M USD | -6.3% | +54.3% | 38.6% | |
| LTM Mar 2026 | $167.29M USD | +17.8% | +13.3% | 24.8% | |
| LTM Mar 2026 | $151.86M USD | -3.5% | -9.1% | 20.7% | |
| LTM Sep 2026 | $111.68M USD | +3.9% | +12.3% | 41.5% | |
| LTM Mar 2026 | $69.57M USD | +28.3% | +38.8% | 25.9% | |
| LTM Sep 2026 | $45.25M USD | +0.0% | — | 50.0% | |
| LTM Sep 2026 | €106.45K EUR | +9.7% | — | — | |
| Peer median (excluding EVO) | — | +8.2% | +9.8% | 38.6% | |
Competitors are the stored peer set for EVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 618.03M | 751.45M | 781.43M | 796.97M | 757.26M |
| Cost of Revenue | 466.49M | 577.38M | 606.38M | 682.09M | 694.6M |
| Gross Profit | 151.54M | 174.07M | 175.05M | 114.88M | 62.66M |
| Gross Margin | 24.5% | 23.2% | 22.4% | 14.4% | 8.3% |
| Research & Development | 65.7M | 76.64M | 68.53M | 50.86M | 74.33M |
| Selling, General & Admin | 105.45M | 156.19M | 169.61M | 188.2M | 123.65M |
| Operating Expenses | 110.55M | 153.22M | 222.56M | 257.4M | 197.97M |
| Depreciation & Amortization | 70.4M | 83.2M | 92.98M | 101.62M | 95.55M |
| EBITDA | 316.63M | (57.61M) | 24.13M | (80.66M) | (13.89M) |
| EBITDA Margin | 51.2% | -7.7% | 3.1% | -10.1% | -1.8% |
| Operating Income | 41M | 20.85M | (47.51M) | (142.52M) | (135.31M) |
| Operating Margin | 6.6% | 2.8% | -6.1% | -17.9% | -17.9% |
| Interest Income | 2.27M | 8.34M | 9.26M | 2.44M | 4.25M |
| Interest Expense | 9.25M | 13.15M | 11.74M | 11.7M | 13.87M |
| Other Income / Expenses | 195.98M | (174.81M) | (33.09M) | (51.46M) | 12M |
| Income Before Tax | 236.98M | (153.96M) | (80.59M) | (193.98M) | (123.31M) |
| Pre-Tax Margin | 38.3% | -20.5% | -10.3% | -24.3% | -16.3% |
| Income Tax Expense | 21.47M | 21.7M | 3.32M | 2.1M | (23.88M) |
| Net Income | 215.51M | (175.66M) | (83.91M) | (196.08M) | (99.43M) |
| Net Margin | 34.9% | -23.4% | -10.7% | -24.6% | -13.1% |
| EPS (Basic) | 0.65 | (0.49) | (0.23) | (0.56) | (0.28) |
| EPS (Diluted) | 0.65 | (0.49) | (0.23) | (0.56) | (0.28) |
| Weighted Avg Shares | 332.81M | 353.35M | 353.87M | 353.29M | 355.16M |
| Weighted Avg Shares (Diluted) | 332.81M | 353.41M | 353.87M | 354.59M | 355.16M |
Evotec SE
NASDAQ:EVO
Intrinsic Alpha fair value
Locked
Current Price
$1.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.